Health supplement marketer Aixin Life International (AIXN.US) withdraws its IPO application in the United States, originally planning to raise $10 million.

Chinese healthcare product distributor Aixin Life International withdrew its initial public offering (IPO) plan on Thursday. The company, originally filed for an IPO in 2023, planned to raise $25 million, and later reduced the fundraising amount to $7 million. Eventually, it increased the fundraising amount to $10 million by issuing 2.5 million shares at a price of $4 per share. The company originally planned to list on the Nasdaq under the ticker symbol AIXN, with Boustead Securities as the sole underwriter for this IPO. Founded in Chengdu, China in 2001, the company generated $4 million in revenue in the 12 months ending September 30, 2024. More critically, as of April 2026, its rolling twelve-month net loss had reached nearly $2.86 million, with a negative gross profit margin, and the company had recently issued multiple compliance warnings for failing to submit annual financial reports on time. It is understood that Aixin Life International's business scope is not limited to healthcare product distribution, but also explores diversification through acquisitions of hotels and other means. However, this business structure has not effectively reversed its financial decline. With the withdrawal of the IPO application, the company will continue to operate in the OTC market. Industry analysts point out that the case of Aixin Life is not unique and reflects the common challenges faced by many small and medium-sized Chinese companies when listing in the US, including challenges with financial transparency, soaring compliance costs, and inadequate liquidity in the secondary market.